Printer Friendly

SEISMED INSTRUMENTS RECEIVES FDA CLEARANCE TO MARKET NEW INTERPRETATION SOFTWARE

 SEISMED INSTRUMENTS RECEIVES FDA CLEARANCE
 TO MARKET NEW INTERPRETATION SOFTWARE
 MINNEAPOLIS, Jan. 22 /PRNewswire/ -- Seismed Instruments (NASDAQ: SEIS) announced today that the company has received a letter from the Food and Drug Administration (FDA) giving the company clearance to begin marketing its new Seismedics Quantitative Analysis Software. The new software is a major milestone in the development of the seismocardiograph and assists physicians in the interpretation of the seismocardiogram.
 Seismed Instruments began clinical trials on the seismocardiograph (SCG) in 1988. The clinical data and the SCG waveforms from these studies were analyzed using a Cray Super Computer. Working with the computer scientists at the Minnesota super computer center who have expertise in neural network analysis, the SCG waveforms have been evaluated, and a software program has been developed that can analyze the changes that occur in the SCG waveform. This software makes it easier for physicians to interpret the results of the exercise SCG test.
 Seismocardiography is a noninvasive test performed in conjunction with routine exercise electrocardiography (ECG) or stress testing. An accelerometer is placed on the sternum of the patient to record vibrational waves generated by the beating heart. A recording is taken before exercise (baseline recording) and another recording is taken after exercise (postexercise recording). The signal averaged waveforms from baseline and postexercise are


compared. Specific changes in the postexercise SCG recording show a high correlation with coronary artery disease. Clinical studies on over 1,800 patients have demonstrated that exercise seismocardiography significantly enhances the diagnostic accuracy of stress testing.
 Sandra Garlough, president and CEO said, "Our new Seismedics Quantitative Anaylsis software makes it much easier for physicians to use our SCG-2000. The software development and FDA clearance now makes it possible for family physicians and internists to use the seismocardiograph in their clinics and offices."
 Seismed Instruments developed a sales and distribution network this past year and the company is now marketing the SCG-2000 seismocardiograph in the U.S. and 12 countries. The system sells for less than $24,000 and can be used at all sites performing stress testing. Seismocardiography is a cost effective approach to improving patient access to new medical technology and helps in the early diagnosis of coronary artery disease.
 Seismed Instruments is a public company traded on NASDAQ under the symbol SEIS. The company was founded in 1987.
 -0- 1/22/92
 /CONTACT: Sandra J. Garlough, president of Seismed Instruments, 612-473-5151/
 (SEIS) CO: Seismed Instruments ST: Minnesota IN: MTC SU:


AL -- MN022 -- 2518 01/22/92 17:12 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 22, 1992
Words:417
Previous Article:MARRIOTT DRAMATICALLY EXPANDS U.K. PRESENCE THROUGH FRANCHISE WITH SCOTT'S HOTELS
Next Article:ALOETTE COSMETICS ANNOUNCES DECLARATION OF FOURTH QUARTER DIVIDEND
Topics:


Related Articles
SEISMED INSTRUMENTS ELECTS NEW BOARD MEMBER
SEISMED INSTRUMENTS ANNOUNCES RESULTS
SEISMED INSTRUMENTS FILES FOR OFFERING OF COMMON STOCK
SEISMED INSTRUMENTS INC STOCKS WILL CONTINUE TO BE LISTED ON THE NASDAQ SMALL-CAP MARKET SYSTEM
SEISMED INSTRUMENTS REPORTS THIRD QUARTER RESULTS
SEISMED INSTRUMENTS INCORPORATED STOCK WILL CONTINUE TO BE LISTED ON NASDAQ SMALL-CAP MARKET SYSTEM
SEISMED INSTRUMENTS ANNOUNCES EXCEPTION EXTENSION FROM NASDAQ REQUIREMENTS AND ACCEPTANCE OF MULTICENTER STUDY FOR PUBLICATION
SEISMED INSTRUMENTS ANNOUNCES FIRST QUARTER RESULTS
SEISMED INSTRUMENTS ELECTS NEW BOARD MEMBERS AND OFFICERS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters